Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC

This study is testing a new type of cell therapy called Universal PSMA CAR-T for men with advanced prostate cancer that no longer responds to standard hormone treatments (called castration-resistant prostate cancer, or CRPC). CAR-T therapy involves modifying immune cells to target a protein called PSMA that is found on prostate cancer cells. This is an early-phase study to assess safety and early signs of effectiveness. **You may be eligible if...** - You are a male between 18 and 80 years old - You have metastatic castration-resistant prostate cancer (cancer that has spread and no longer responds to hormone therapy) - You have already received one or more standard CRPC treatments (such as hormone therapies, chemotherapy, or radium-223) - Your expected survival is more than 6 months - Your general health and organ function meet the study requirements **You may NOT be eligible if...** - You have active autoimmune disease or a compromised immune system - You have uncontrolled infections - You have received certain prior treatments that would interfere with CAR-T therapy - You have significant heart, lung, liver, or kidney problems - You have active brain metastases Talk to your doctor to see if this trial is right for you.